Treatment of porphyria cutanea tarda with oral thalidomide.
Eight male patients with overt clinical and biochemical features of porphyria cutanea tarda (PCT) were orally treated with 300 mg/day thalidomide for 1 week and with 200 mg/day for 3 more weeks. Already after the first week of treatment no new vesicles and/or bullae could be observed. Spontaneous blisters completely disappeared, increased skin fragility subsided and skin hyperpigmentation receded about 2 months after completion of therapy, whereas hypertrichosis persisted. There was a rapid decrease in the urinary total porphyrin excretion which reached normal levels in all patients by the end of the fourth week of therapy, whereas the posttreament chromatographic pattern of urinary porphyrins revealed a slight reduction of higher carboxylated porphyrin metabolites and an increase in the amount of the excreted coproporphyrin, as compared to the pretreatment period. Somnolence, intermittent constipation and dry mouth occurred in all patients, 2 patients additionally experienced dizziness. No evidence of peripheral neuropathy could be detected and laboratory investigations revealed no abnormalities, as compared to the pretreatment period. During the 16- to 28-month follow-up of the patients, no clinical or biochemical relapse was observed. In view of the encouraging results of the present investigation, further studies are now warranted in order to definitely answer the question whether oral thalidomide may be regarded as an effective alternative approach to the treatment of PCT.
Monastirli
A
A
Department of Dermatology, University of Patras, Greece.
Georgiou
S
S
Bolsen
K
K
Pasmatzi
E
E
Papapanagiotou
A
A
Goerz
G
G
Kalofoutis
A
A
Merk
H F
HF
Tsambaos
D
D
D000284:Administration, Oral; D000328:Adult; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000188:drug therapy* / Q000473:pathology; D011166:Porphyrins / Q000652:urine; D012867:Skin / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D007917:Leprostatic Agents; D011166:Porphyrins; D013792:Thalidomide